Related Experiment Video
Updated: Jan 20, 2026

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
Published on: September 9, 2020
Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies
Ian W Folkert1, Samir Devalaraja2, Gerald P Linette3
1Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
Primary malignant bone tumors are rare, occur in all age groups, and include distinct entities such as osteosarcoma, Ewing sarcoma, and chondrosarcoma. Traditional treatment with some combination of chemotherapy, surgery, and radiation has reached the limit of efficacy, with substantial room for improvement in patient outcome. Furthermore, genomic characterization of these tumors reveals a paucity of actionable molecular targets. Against this backdrop, recent advances in cancer immunotherapy represent a silver lining in the treatment of primary bone cancer. Major strategies in cancer immunotherapy include stimulating naturally occurring anti-tumor T cells and adoptive transfer of tumor-specific cytotoxic T cells. Chimeric antigen receptor T cells (CAR-T cells) belong to the latter strategy and are an impressive application of both insights into T cell biology and advances in genetic engineering. In this review, we briefly describe the CAR-T approach and discuss its applications in primary bone tumors. © 2019 American Society for Bone and Mineral Research.
Insights
Chimeric antigen receptor T cells (CAR-T cells) offer a promising new avenue for treating rare primary bone cancers. This immunotherapy approach involves engineering T cells to target and destroy tumor cells, potentially improving patient outcomes where traditional treatments fall short.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Primary malignant bone tumors, including osteosarcoma, Ewing sarcoma, and chondrosarcoma, are rare and affect all age groups.
- Current treatments like chemotherapy, surgery, and radiation have limited efficacy and significant room for improvement.
- Genomic studies show a lack of actionable molecular targets in these bone cancers.
Purpose of the Study:
- To review the application of Chimeric Antigen Receptor T cells (CAR-T cells) in treating primary bone tumors.
- To highlight immunotherapy as a novel strategy for rare bone cancers with limited therapeutic options.
Main Methods:
- This review discusses the CAR-T cell approach, a type of adoptive T cell transfer.
- It summarizes current research and potential applications of CAR-T cells in bone cancer therapy.
Main Results:
- CAR-T cell therapy represents a significant advancement in cancer immunotherapy.
- It leverages T cell biology and genetic engineering for targeted anti-tumor activity.
Conclusions:
- CAR-T cell therapy shows potential as a novel treatment strategy for primary bone cancers.
- Further research and clinical application are warranted to improve outcomes for patients with these rare malignancies.
Related Concept Videos
Gene Therapy
Group Therapy
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Drug Therapy
Antianxiety Medications
Cognitive Therapy
Electroconvulsive Therapy

